Pfizer Japan began the commercial rollout of its oral COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) on March 22, making it available under the normal wholesaler distribution channel in the country.

Pfizer Japan Starts Commercial Rollout of COVID-19 Pill Paxlovid

People who are vaccinated or who take Paxlovid during a Covid-19 infection have a lower risk of developing long Covid, new research shows.

Vaccination, Paxlovid decrease risk of long Covid, studies show

In a recent study published in the JAMA Health Forum, researchers in the United States estimated the reduction in coronavirus disease 2019 (COVID-19) mortality rates after the Paxlovid rollout.

Higher Paxlovid uptake in winter 2022 could have prevented nearly 5,000 deaths

The antiviral nirmatrelvir, which is part of Paxlovid, was linked to a significant reduction in the risk for long COVID and post-acute death in patients with at least one risk factor for severe illness, according to researchers.Recent research has indicated that nearly 19 million adults in the United States may have long COVID. The condition has had a substantial impact on patients, many of whom have been unable to return to work since their diagnosis. The most common symptoms include headache, fatigue and brain fog, but there are many others that can be tied to long COVID.Yan Xie, PhD,

Antiviral associated with 26% reduced risk for long COVID

In a recent study published in The Lancet’s Infectious Diseases, researchers in the United States evaluated nirmatrelvir–ritonavir treatment effectiveness against hospitalizations and deaths among coronavirus disease 2019 (COVID-19) outpatients in the United States of America (USA).

Paxlovid is 80% effective when taken within 5 days of severe COVID

WALTHAM, Mass., March  22, 2023  (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the publication of research in the peer-reviewed journal Science Translational Medicine describing a model for evaluating biomarker correlates of protection for monoclonal antibodies (mAb) against symptomatic COVID-19. The research concluded that neutralizing antibodies are mechanistic in providing protection against symptomatic disease and identified serum neutralizing antibody titers as a correlate of protection. These findings have potential to support accelerated development and innovative regulatory frameworks for mAbs for prevention of COVID-19.

antiviral news

Press Releases in the global landscape